Computational approaches: discovery of GTPase HRas as prospective drug target for 1,3-diazine scaffolds

Springer Science and Business Media LLC - Tập 13 - Trang 1-13 - 2019
Sanjiv Kumar1, Deepika Sharma1, Balasubramanian Narasimhan1, Kalavathy Ramasamy2,3, Syed Adnan Ali Shah2,4, Siong Meng Lim2,3, Vasudevan Mani5
1Faculty of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, India
2Faculty of Pharmacy, Universiti Teknologi MARA (UiTM), Bandar Puncak Alam, Malaysia
3Collaborative Drug Discovery Research (CDDR) Group, Pharmaceutical Life Sciences Community of Research, Universiti Teknologi MARA (UiTM), Shah Alam, Malaysia
4Atta-ur-Rahman Institute for Natural Products Discovery (AuRIns), Universiti Teknologi MARA, Bandar Puncak Alam, Malaysia
5Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraidah, Kingdom of Saudi Arabia

Tóm tắt

Heterocyclic 1,3-diazine nucleus is a valuable pharmacophore in the field of medicinal chemistry and exhibit a wide spectrum of biological activities. PharmMapper, a robust online tool used for establishing the target proteins based on reverse pharmacophore mapping. PharmMapper study is carried out to explore the pharmacological activity of 1,3-diazine derivatives using reverse docking program. PharmMapper, an open web server was used to recognize for all the feasible target proteins for the developed compounds through reverse pharmacophore mapping. The results were analyzed via molecular docking with maestro v11.5 (Schrodinger 2018-1) using GTPase HRas as possible target. The molecular docking studies displayed the binding behavior of 1,3-diazine within GTP binding pocket. From the docking study compounds s3 and s14 showed better docked score with anticancer potency against cancer cell line (HCT116). Hence, the GTPase HRas may be the possible target of 1,3-diazine derivatives for their anticancer activity where the retrieved information may be quite useful for developing rational drug designing. Furthermore the selected 1,3-diazine compounds were evaluated for their in vitro anticancer activity against murine macrophages cell line. 1,3-Diazine compounds exhibited good selectivity of the compounds towards the human colorectal carcinoma cell line instead of the murine macrophages. The toxicity study of the most active compounds was also performed on non cancerous HEK-293 cell line.

Tài liệu tham khảo

Ghorab MM, Alsaid MS (2016) Anticancer activity of some novel thieno[2,3-d]pyrimidine derivatives. Biomed Res 27(1):110–115 Cieplik J, Stolarczyk M, Pluta J, Gubrynowicz O, Bryndal I, Lis T, Mikulewicz M (2011) Synthesis and antibacterial properties of pyrimidine derivatives. Acta Pol Pharm Drug Res 68(1):57–65 Nofal ZM, Fahmy HH, Zarea ES, El-Eraky W (2011) Synthesis of new pyrimidine derivatives with evaluation of their anti-inflammatory and analgesic activities. Acta Pol Pharm Drug Res 68(4):507–517 Gupta YK, Gupta V, Singh S (2013) Synthesis, characterization and antimicrobial activity of pyrimidine based derivatives. J Pharm Res 7:491–495 Bhat AR (2017) Biological activity of pyrimidine derivatives: a review. Organ Med Chem 2(2):1–4 Ott JJ, Ullrich A, Mascarenhas M, Stevens GA (2010) Global cancer incidence and mortality caused by behavior and infection. J Public Health 33(2):223–233 Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S (2014) Drug resistance in cancer: an overview. Cancers 6:1769–1792 Pagadala NS, Syed K, Tuszynski J (2017) Software for molecular docking: a review. Biophys Rev 9:91–102 Bassyouni F, Hefnawi ME, Rashed AE, Rehim MA (2017) Molecular modeling and biological activities of new potent antimicrobial, anti-inflammatory and anti-nociceptive of 5-nitro indoline-2-one derivatives. Drug Des 6(2):1–6 Yousif MNM, El-Sayed WA, Abbas HAS, Awad HM, Yousif NM (2017) Anticancer activity of new substituted pyrimidines, their thioglycosides and thiazolopyrimidine derivatives. J Appl Pharm Sci 7(11):021–032 Mohamed MS, Youns MM, Ahmed NM (2015) Evaluation of anticancer activity of some thiouracil derivatives. Int J Pharm Biol Sci 5(4):159 Mohamed AM, Al-Qalawi HRM, El-Sayed WA, Arafa WAA, Alhumaimess MS, Hassan AK (2015) Anticancer activity of newly synthesized triazolopyrimidine derivatives and their nucleoside analogs. Acta Pol Pharm 72(2):307–318 Kumar S, Lim SM, Ramasamy K, Mani V, Shah SAA, Narasimhan B (2018) Design, synthesis, antimicrobial and cytotoxicity study on human colorectal carcinoma cell line of new 4,4′-(1,4-phenylene)bis(pyrimidin-2-amine) derivatives. Chem Cent J 12(73):1–13 Kumar S, Singh J, Narasimhan B, Shah SAA, Lim SM, Ramasamy K, Mani V (2018) Reverse pharmacophore mapping and molecular docking studies for discovery of GTPase HRas as promising drug target for bis-pyrimidine derivatives. Chem Cent J 12(106):1–11 Driessche GVD, Fourches D (2017) Adverse drug reactions triggered by the common HLA-B*57:01 variant: a molecular docking study. J Cheminform 9(13):1–17 Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W (2013) Protein and ligand preparation: parameters, protocols and influence on virtual screening enrichments. J Comput Aid Mol Des 27(3):221–234 Sharma V, Sharma PC, Kumar V (2016) In silico molecular docking analysis of natural pyridoacridines as anticancer agents. Adv Chem 2016:1–9 Friesner RA, Murph RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein–ligand complexes. J Med Chem 49:6177–6196 Lenselink EB, Louvel J, Forti AF, van Veldhoven JPD, de Vries H, Mulder-Krieger T, McRobb FM, Negri A, Goose J, Abel R, van Vlijmen HWT, Wang L, Harder E, Sherman W, IJzerman AP, Beuming T (2016) Predicting binding affinities for GPCR ligands using free-energy perturbation. ACS Omega 1:293–304 Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107–1112 Selvaraj V, Bodapati S, Murray E, Rice KM, Winston N, Shokuhfar T, Zhao Y, Blough E (2014) Cytotoxicity and genotoxicity caused by yttrium oxide nanoparticles in HEK293 cells. Int J Nanomed 9:1379–1391 Ge S-M, Zhan DL, Zhang S-H, Song L-Q, Han W-W (2016) Reverse screening approach to identify potential anti-cancer targets of dipyridamole. Am J Transl Res 8(12):5187–5198 Wang X, Shen Y, Wang S, Li S, Zhang W, Liu X, Lai L, Pei J, Li H (2017) PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res 45(W1):W356–W360 Wang X, Pan C, Gong J, Liu X, Li H (2016) Enhancing the enrichment of pharmacophore-based target prediction for the polypharmacological profiles of drugs. J Chem Inf Model 56(6):1175–1183 Colicelli J (2004) Human RAS superfamily proteins and related GTPases. Sci STKE 250:1–13